334 related articles for article (PubMed ID: 23533247)
21. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
[TBL] [Abstract][Full Text] [Related]
22. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
23. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
[TBL] [Abstract][Full Text] [Related]
24. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
25. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
26. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
[TBL] [Abstract][Full Text] [Related]
27. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
28. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
[TBL] [Abstract][Full Text] [Related]
29. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
30. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
31. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
[TBL] [Abstract][Full Text] [Related]
32. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
33. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
[TBL] [Abstract][Full Text] [Related]
34. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
35. Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Chen D; Shen Z; Cheng X; Wang Q; Zhou J; Ren F; Sun Y; Wang H; Huang R
Bioengineered; 2021 Dec; 12(1):1964-1975. PubMed ID: 34027794
[TBL] [Abstract][Full Text] [Related]
36. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
37. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
38. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
39. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
40. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
